Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous human immunoglobulin (Cutaquig) at modified dosing regimens in primary immunodeficiency
2019-002999-13Phase 3
- Sponsor
- Octapharma
- Start
- Jul 2019
- Countries
- 1
01
Overview
Phase 3, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, sponsored by Octapharma. Primary endpoints: Total IgG trough levels on modified regimens vs weekly dosing and Infection-related efficacy outcomes.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2019-002999-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002999-13.